CTRI/2009/091/000360招募中3 期
A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory Impairment
试验速览
- 阶段
- 3 期
- 状态
- 招募中
- 入组人数
- 135
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
入选标准
- •Urinary incontinence as a result of neurogenic overactive bladder
- •due to spinal cord injury or multiple sclerosis
- •- Inadequate response to anticholinergic medication used to treat
- •overactive bladder.
- •- Respiratory impairment and abnormal pulmonary function test
排除标准
- •- History or evidence of pelvic or urologic abnormality
- •- Previous or current diagnosis of bladder or prostate cancer
- •- Symptomatic or untreated urinary tract infection at time of
研究者
相似试验
进行中（未招募）
不适用
A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory ImpairmentPatients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy and have neurological respiratory impairment.MedDRA version: 8.1Level: LLTClassification code 10046543Term: Urinary incontinenceEUCTR2006-006299-39-NLAllergan135
进行中（未招募）
1 期
A Placebo-Controlled, Randomized, Safety and Efficacy Study of BOTOX® (Botulinum Toxin Type A) Purified Neurotoxin Complex in Patients with Neurogenic Detrusor Overactivity and Neurological Respiratory ImpairmentPatients with urinary incontinence due to neurogenic detrusor overactivity as a result of spinal cord injury or multiple sclerosis who have not been adequately managed with anticholinergic therapy and have neurological respiratory impairment.MedDRA version: 8.1Level: LLTClassification code 10046543Term: Urinary incontinenceEUCTR2006-006299-39-FRAllergan135
撤回
3 期
A placebo-controlled, randomized, safety and efficacy study of BOTOX® (Bolulinum Toxin Type A) Purified Neurotoxin Complex in patients with neurogenic detrusor overactivity and neurological respiratory impairment.Neurogenic Overactive Bladder: urine incontinence due to illness or damage of the spinal cord1004154310038716NL-OMON31185Allergan5
已完成
1 期
A Phase 1 study to evaluate Safety, Tolerability and Pharmacokinetics of LMR-123 in Healthy SubjectsAcute Ischemic StrokeStroke - IschaemicACTRN12619001609145Australia Medical Industries Pty Ltd.52
已完成
不适用
Safety and pharmacodynamics of KB002, an anti granulocyte monocyte colony stimulating factor (GM-CSF) monoclonal antibody, in patients with persistent symptomatic asthmaPersistent symptomatic asthmaRespiratory - AsthmaACTRN12607000554460Kalobios Pharmaceuticals Inc.24